PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 23 filers reported holding PROQR THRAPEUTICS N V in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $1,900,000 | -76.2% | 346,148 | -57.0% | 0.24% | -63.8% |
Q4 2019 | $7,978,000 | +51.4% | 805,000 | -12.0% | 0.66% | -19.3% |
Q3 2019 | $5,270,000 | +23.2% | 915,000 | +94.7% | 0.81% | +39.1% |
Q2 2019 | $4,277,000 | +62.3% | 470,000 | +147.4% | 0.58% | +142.7% |
Q1 2019 | $2,635,000 | -50.9% | 190,000 | -44.1% | 0.24% | -60.2% |
Q4 2018 | $5,365,000 | -30.5% | 340,000 | -14.7% | 0.60% | -31.7% |
Q3 2018 | $7,716,000 | +114.1% | 398,749 | -19.2% | 0.89% | +78.3% |
Q2 2018 | $3,604,000 | +78.0% | 493,749 | -25.0% | 0.50% | +61.9% |
Q1 2018 | $2,025,000 | +18.5% | 658,500 | +24.2% | 0.31% | +52.7% |
Q4 2017 | $1,709,000 | -33.5% | 530,000 | 0.0% | 0.20% | -45.2% |
Q3 2017 | $2,571,000 | +49.8% | 530,000 | +60.6% | 0.37% | +25.7% |
Q2 2017 | $1,716,000 | +4.0% | 330,000 | 0.0% | 0.29% | -9.6% |
Q1 2017 | $1,650,000 | +68.4% | 330,000 | +65.0% | 0.32% | +30.2% |
Q4 2016 | $980,000 | -24.7% | 200,000 | +33.3% | 0.25% | +29.8% |
Q4 2015 | $1,302,000 | -53.8% | 150,000 | +15.4% | 0.19% | -60.2% |
Q4 2014 | $2,817,000 | -18.1% | 130,000 | -35.0% | 0.48% | +12.9% |
Q3 2014 | $3,438,000 | – | 200,000 | – | 0.42% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Privium Fund Management B.V. | 5,344,446 | $4,156,000 | 1.38% |
Prosight Management, LP | 1,707,509 | $1,328,000 | 1.05% |
Opaleye Management Inc. | 2,740,000 | $2,131,000 | 0.96% |
M28 Capital Management LP | 1,001,800 | $779,000 | 0.87% |
Monaco Asset Management SAM | 931,400 | $724,000 | 0.32% |
APOGEM CAPITAL LLC | 125,273 | $97,000 | 0.09% |
Ground Swell Capital, LLC | 21,640 | $17,000 | 0.03% |
FRANKLIN STREET ADVISORS INC /NC | 150,000 | $117,000 | 0.01% |
Atom Investors LP | 30,422 | $24,000 | 0.01% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,300,000 | $2,566,000 | 0.01% |